VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Standard BioTools Inc. (LAB) Total Return Calculator with Dividends Reinvested

Standard BioTools Inc.

Popular:

The total return for Standard BioTools Inc. (LAB) stock is -1.96% over the past 12 months. So far it's down 21.26% this year. The 5-year total return is -80.51%, meaning $10,000 invested in LAB stock 5 years ago would be worth $1,949 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in LAB 1 year ago, it would be worth $8,929 today — you'd have lost $1,071.

With Dividends Reinvested$8,929-10.71%

Price Only (No DRIP)$8,929-10.71%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in LAB

1Y$9,804-$196 (-2.0%)-2.0% CAGR

3Y$6,061-$3,939 (-39.4%)-15.4% CAGR

5Y$1,949-$8,051 (-80.5%)-27.9% CAGR

10Y$1,095-$8,905 (-89.0%)-19.8% CAGR

15Y$625-$9,375 (-93.8%)-16.9% CAGR

20Y$713-$9,287 (-92.9%)-12.4% CAGR

30Y$713-$9,287 (-92.9%)-8.4% CAGR

Standard BioTools Inc. did not pay dividends during this period. Total return = price return.

Loading LAB total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-21.26%	—	-21.26%	—	$7,874
1Y	-1.96%	-1.96%	-1.96%	—	$9,804
3Y	-39.39%	-15.37%	-39.39%	—	$6,061
5Y	-80.51%	-27.89%	-80.51%	—	$1,949
10Y	-89.05%	-19.84%	-89.05%	—	$1,095
15Y	-93.75%	-16.88%	-93.75%	—	$625
20Y	-92.87%	-12.37%	-92.87%	—	$713
30Y	-92.87%	-8.43%	-92.87%	—	$713

Risk & Highlights

Best Year+164.00%2013

Worst Year-68.55%2022

Max Drawdown-47.47%2025-12-22 → 2026-04-13

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-11.02%	-11.02%	—	+0.41%	-11.4pp
2025	-26.86%	-26.86%	—	+16.64%	-43.5pp
2024	-21.17%	-21.17%	—	+24.00%	-45.2pp
2023	+70.00%	+70.00%	—	+24.81%	+45.2pp
2022	-68.55%	-68.55%	—	-19.95%	-48.6pp

LAB underperformed the S&P 500 by 32.33pp over the past year (-1.96% vs +30.37%).

Loading summary...

LAB Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
LABStandard BioTools Inc.	$390M	+8.1%	-21.3%	-2.0%	—	-39.4%	-80.5%	-89.0%
AZTAAzenta, Inc.	$855M	-14.5%	-44.4%	-26.5%	—	-59.1%	-81.0%	+123.4%
NTRANatera, Inc.	$31.2B	+5.0%	-3.9%	+37.3%	—	+314.0%	+115.9%	+2089.4%
PACBPacific Biosciences of California, Inc.	$498M	+14.6%	-10.3%	+46.0%	—	-86.5%	-93.4%	-81.3%
SEERSeer, Inc.	$105M	+11.2%	+3.3%	+1.6%	—	-47.2%	-95.1%	-96.7%
CDNACareDx, Inc	$1.1B	+21.3%	+12.0%	+45.2%	—	+161.1%	-72.4%	+385.1%
ILMNIllumina, Inc.	$21.1B	+9.7%	+3.2%	+81.7%	—	-27.1%	-62.8%	+0.7%
TMOThermo Fisher Scientific Inc.	$176.4B	-3.1%	-19.8%	+16.8%	+0.4pp	-11.7%	+2.8%	+229.1%
DHRDanaher Corporation	$124.3B	-8.0%	-23.6%	-8.3%	+0.7pp	-15.5%	-21.1%	+219.3%
BIOBio-Rad Laboratories, Inc.	$6.9B	-7.4%	-15.7%	+10.7%	—	-32.0%	-57.7%	+81.4%
BRKRBruker Corporation	$6.7B	+19.3%	-9.0%	+7.8%	+0.5pp	-42.5%	-35.5%	+67.1%

Compare:LAB vs AZTA LAB vs NTRA LAB vs PACB LAB vs AZTA vs NTRA

About LAB Dividend Returns

Standard BioTools Inc. (LAB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of LAB over the past year?

Standard BioTools Inc. (LAB) delivered a return of -1.96% over the past year. Since LAB does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in LAB be worth today?

A $10,000 investment in Standard BioTools Inc. one year ago would be worth $9,804 today, representing a loss of $196.

Q3Does LAB pay dividends?

Standard BioTools Inc. (LAB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For LAB, the total return equals the price-only return.

Q4Did LAB beat the S&P 500?

No, Standard BioTools Inc. (LAB) underperformed the S&P 500 by 32.33 percentage points over the past year. LAB delivered a total return of -1.96%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed LAB by 32.33pp during this period.

Q5What is LAB's worst drawdown?

Standard BioTools Inc. (LAB) experienced a maximum drawdown of -47.47% over the past year, declining from its peak on 2025-12-22 to its trough on 2026-04-13. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is LAB's long-term total return over 10, 20, or 30 years?

Here are Standard BioTools Inc. (LAB)'s long-term returns with dividends reinvested. Over 10 years, the total return is -89.0% (-19.8% CAGR) — $10,000 would have grown to $1,095. Over 20 years: -92.9% total return (-12.4% CAGR) — $10,000 → $713. Over 30 years: -92.9% total return (-8.4% CAGR) — $10,000 → $713. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was LAB's best and worst year?

Standard BioTools Inc.'s best calendar year was 2013 with a total return of 164.0%. Its worst year was 2022 with a total return of -68.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 232.5 percentage points.